Chimeric Antigen Receptor T (CAR T) are T-cells that are genetically engineered and are used in cell therapy. Our expert team of scientists is committed to provide a wide range of services in CAR T-cell therapy research.
CAR Designing
- CAR discovery (scFv / vHH) and screening
- 2nd / 3rd / 4th generation CARs designing (ScFV /vHH / linkers/co-stimulatory domain testing / safety switches / standard designs)
- Dual/bi-specific CAR and universal / allogeneic CARs
CAR T Generation
- Viral vector system (lentivirus/retrovirus)
- Non-viral system (synthetic mRNA/ transposon)
- Transduction/transfection of primary T-cells from healthy donors
CAR T Manufacturing Process Optimization
- Media, cytokines and growth factors screening for ex vivo CAR T-cell manufacturing process optimization
CAR T Characterization
- CAR detection (% CAR+ T-cells) by flow cytometry
- Vector copy number (VCN) by ddPCR/ qRT-PCR
- Immunophenotyping (%CD3+/%CD4+, (%CD3+/%CD8+ CAR-T cells), %TN, %TSCM, %TCM, %TEM and %TE during and after ex vivo CAR-T expansion
- Activation (CD25) and exhaustion marker (PD-1, LAG-3, TIM3, CTLA-4) analysis
In vitro CAR T Screening
- CAR-T proliferation (recombinant protein or co-culture (E:T) assay)
- Cytotoxicity assay /co-culture (different E:T ratio) using target expressing parental or reporter cell lines
- T-cell activation (CD25) marker analysis
- T-cell exhaustion marker analysis (PD-1, LAG-3, TIM3, CTLA-4)
- Inflammatory cytokine profiling (IL-2, IFN-y and TNF-a, CD107 a/b)
In vivo CAR T Efficacy
- Tumor clearance study in orthotopic systemic NOD-SCID xenograft model (B-cell malignancies)
- Immunophenotyping of circulation CAR-T cells
- CAR-T activation, proliferation and persistence assessment by flow cytometry and Vector Copy Number (VCN) analysis
- Cytokine profiling (IL-2, IFN-y and TNF-a)
Reagent Generation for CAR T
- Lentivirus, retrovirus, synthetic mRNA, transposon system, KI/KO cell lines and reagent proteins
Why Aurigene Pharmaceutical Services?
CAR discovery
CAR designing and screening
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Contact Us
Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...
Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...
Read More
Technology meets sustainability - How a complex API development process goes green
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...
Read MoreAlternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2023
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2021
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2021
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More -
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
2021
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.